Literature DB >> 33452380

Mycobacterium tuberculosis Rv3160c is a TetR-like transcriptional repressor that regulates expression of the putative oxygenase Rv3161c.

Hasan Tükenmez1,2,3,4, Souvik Sarkar5,6, Saber Anoosheh5,6, Anastasiia Kruchanova7,6, Isabel Edström7,6, Gregory A Harrison8, Christina L Stallings8, Fredrik Almqvist5,6, Christer Larsson9,10,11.   

Abstract

Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is a major health threat listed among the top 10 causes of death worldwide. Treatment of multidrug-resistant Mtb requires use of additional second-line drugs that prolong the treatment process and result in higher death rates. Our team previously identified a 2-pyridone molecule (C10) that blocks tolerance to the first-line drug isoniazid at C10 concentrations that do not inhibit bacterial growth. Here, we discovered that the genes rv3160c and rv3161c are highly induced by C10, which led us to investigate them as potential targets. We show that Rv3160c acts as a TetR-like transcriptional repressor binding to a palindromic sequence located in the rv3161c promoter. We also demonstrate that C10 interacts with Rv3160c, inhibiting its binding to DNA. We deleted the rv3161c gene, coding for a putative oxygenase, to investigate its role in drug and stress sensitivity as well as C10 activity. This Δrv3161c strain was more tolerant to isoniazid and lysozyme than wild type Mtb. However, this tolerance could still be blocked by C10, suggesting that C10 functions independently of Rv3161c to influence isoniazid and lysozyme sensitivity.

Entities:  

Year:  2021        PMID: 33452380      PMCID: PMC7810876          DOI: 10.1038/s41598-021-81104-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  32 in total

1.  Conformational changes of the Tet repressor induced by tetracycline trapping.

Authors:  P Orth; F Cordes; D Schnappinger; W Hillen; W Saenger; W Hinrichs
Journal:  J Mol Biol       Date:  1998-06-05       Impact factor: 5.469

2.  Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance.

Authors:  W Hinrichs; C Kisker; M Düvel; A Müller; K Tovar; W Hillen; W Saenger
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

3.  Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.

Authors:  Joshua Odingo; Theresa O'Malley; Edward A Kesicki; Torey Alling; Mai Ann Bailey; Julie Early; Juliane Ollinger; Suryakanta Dalai; Naresh Kumar; Ravindra Vikram Singh; Philip A Hipskind; Jeffrey W Cramer; Thomas Ioerger; James Sacchettini; Richard Vickers; Tanya Parish
Journal:  Bioorg Med Chem       Date:  2014-10-22       Impact factor: 3.641

4.  The Tetracycline Repressor-A Paradigm for a Biological Switch.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  2000-06-16       Impact factor: 15.336

5.  Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis.

Authors:  Catherine Vilchèze; Travis Hartman; Brian Weinrick; Paras Jain; Torin R Weisbrod; Lawrence W Leung; Joel S Freundlich; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-10       Impact factor: 11.205

6.  The complex formed between Tet repressor and tetracycline-Mg2+ reveals mechanism of antibiotic resistance.

Authors:  C Kisker; W Hinrichs; K Tovar; W Hillen; W Saenger
Journal:  J Mol Biol       Date:  1995-03-24       Impact factor: 5.469

7.  Global analyses of TetR family transcriptional regulators in mycobacteria indicates conservation across species and diversity in regulated functions.

Authors:  Ricardo J C Balhana; Ashima Singla; Mahmudul Hasan Sikder; Mike Withers; Sharon L Kendall
Journal:  BMC Genomics       Date:  2015-06-27       Impact factor: 3.969

8.  Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening.

Authors:  Hasan Tükenmez; Isabel Edström; Ramesh Ummanni; Stina Berglund Fick; Charlotta Sundin; Mikael Elofsson; Christer Larsson
Journal:  Sci Rep       Date:  2019-01-10       Impact factor: 4.379

9.  Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Authors:  Guido V Bloemberg; Peter M Keller; David Stucki; David Stuckia; Andrej Trauner; Sonia Borrell; Tsogyal Latshang; Mireia Coscolla; Thomas Rothe; Rico Hömke; Claudia Ritter; Julia Feldmann; Bettina Schulthess; Sebastien Gagneux; Erik C Böttger
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

10.  Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in Mycobacterium tuberculosis.

Authors:  Teresa Cortes; Olga T Schubert; Graham Rose; Kristine B Arnvig; Iñaki Comas; Ruedi Aebersold; Douglas B Young
Journal:  Cell Rep       Date:  2013-11-21       Impact factor: 9.423

View more
  1 in total

Review 1.  Applications of Transcriptomics and Proteomics for Understanding Dormancy and Resuscitation in Mycobacterium tuberculosis.

Authors:  Manikuntala Kundu; Joyoti Basu
Journal:  Front Microbiol       Date:  2021-03-31       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.